OBX

Obsidian Therapeutics Inc

12.56

Nov 13 • 3:59 PM ET +0.08 (0.64%)

12.56

Aftermarket • 5:00 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Nov 12, 6:46 PMObsidian Therapeutics reports fiscal Q3 2026 non-GAAP EPS of -$1.23, missing estimates

Peers: IOVA IMTX LYEL ARTV LEGN REPL TIL TCRX NKTX ACET

| Held by: VTI VXF SCHA ITOT SCHB ONEQ TNXT

Scroll to Statements

Index	-
Market Cap	775.87M
Enterprise Value	565.01M
Income	74.98M
Sales	0.00M
Book/sh	5.19
Cash/sh	3.48
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	3
IPO	Nov 07, 2019

P/E	0.08
Forward P/E	-
PEG	-
P/S	-
P/B	2.42
P/C	3.61
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	12.29
Current Ratio	12.29
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	No / Yes

EPS (ttm)	163.45
EPS next Y	-
EPS next Q	-0.85
EPS this Y	-
EPS next Y	-
EPS next 5Y	76.23%
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	469.96%
Sales Y/Y TTM	-
EPS Q/Q	56.19%
Sales Q/Q	-
Earnings	Nov 12 AMC
EPS/Sales Surpr.	-138.56% -

Insider Own	12.40%
Insider Trans	0.00%
Inst Own	22.77%
Inst Trans	20.11%
ROA	43.37%
ROE	86.21%
ROIC	23.25%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-5.75%
SMA50	-12.06%
SMA200	-14.37%
Trades

Shs Outstand	61.77M
Shs Float	54.11M
Short Float	2.19%
Short Ratio	2.41
Short Interest	1.18M
52W High	49.97 -74.86%
52W Low	4.00 214.00%
Volatility	18.93% 12.94%
ATR (14)	1.64
RSI (14)	45.53
Beta	3.12
Rel Volume	0.64
Avg Volume	491.14K
Volume	314,049

Perf Week	-9.41%
Perf Month	2.95%
Perf Quarter	-28.37%
Perf Half Y	-37.20%
Perf YTD	185.45%
Perf Year	164.98%
Perf 3Y	-53.86%
Perf 5Y	-96.35%
Perf 10Y	-
Recom	1.00
Target Price	39.00
Prev Close	12.48
Price	12.56
Change %	0.64%

Consensus

Strong Buy

Avg. Price Target

$39.00

Implied Upside

+210.5%

Analysts4incl. previous ratings

Rating Distribution4 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 22, 2026	Initiated	LLeerink Partners	Outperform	$32	+154.8%
Sep 09, 2026	Initiated	WWilliam Blair	Outperform
Aug 06, 2026	Initiated	TTD Cowen	Buy
Aug 05, 2026	Initiated	PPiper Sandler	Overweight	$42	+234.4%

Nov-12-26 03:05PM	Obsidian Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates (Business Wire)
Nov-06-26 08:05AM	Obsidian Therapeutics to Present Updated Amsoki-cel Efficacy and Pooled Safety Data in Advanced Melanoma at SITC 2026 Annual Meeting (Business Wire) +44.43%
Oct-02-26 09:05AM	Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual Meeting (Business Wire)
Aug-06-26 09:48AM	Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls (The Fly)
Aug-05-26 09:40AM	Best Buy downgraded, Bristol Myers upgraded: Wall Street's top analyst calls (The Fly) -16.15%
07:05AM	Loading…
07:05AM	Obsidian Therapeutics Announces First Patient Enrolled in the Registration-enabling Cohort of Phase 1/2 Agni-01 Study Evaluating Amsoki-cel (OBX-115) in Advanced Melanoma (Business Wire)

Obsidian Therapeutics Inc. engages in developing cell and gene therapies, particularly for the treatment of solid tumors and cancer. The company was founded on September 29, 2015 and is headquartered in Malvern, PA.

Ph.D.Dr. Maria Fardis M.B.A.

M.S.Dr. Madan Jagasia M.D.

Chief Technical OfficerMr. Dana M. Alexander M.B.A.

M.S.Dr. Parameswaran Hari M.D.

Chief Financial OfficerMs. Julie B. Feder

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

OBX

Obsidian Therapeutics Inc

Upgrade your Finviz experience

All the Features.
Half the Price.